Westminster to hold Public Lecture on use of cannabis in the treatment of epilepsy
Biomedical Sciences 31 August 2017
Epilepsy is a devastating neurological condition that has affected humanity from time immemorial. Treatment throughout this time has been wide-ranging in nature, with varied level of success. More recently there has been a resurgence in the interest in the use of cannabis in the treatment of epilepsy. A number of clinical trials, with cannabis derived compounds such as Cannabidiol (CBD) having significant therapeutic benefits in neurologic conditions such as epilepsy. However, there still is a significant research paucity in our understanding of the use of medical cannabis in epilepsy.
In this free half-day evening symposium on the University’s Cavendish Campus in Fitzrovia, Central London, Professor Geoffrey Guy will give a historical overview of the use of cannabis and cannabis derived products in the treatment of epilepsy and will present and discuss the latest research in this sometime contentious, yet rapidly expanding, area of social, scientific and medical importance.
Professor Geoffrey Guy is the founder and owner of GW Pharma, a highly successful biotech company and one of the world leaders in the development and commercialisation of herb-derived medicines, including cannabinoids. Professor Guy is also an outstanding scientist who has worked closely with leading scientific institutions, including the University of Westminster, in determining the mode-of-action of some of these natural compounds and their effects on health and disease. He has published widely, with many highly cited papers and reviews in the area of cannabinoids and mitochondrial function.
Professor Guy has been collaborating with the University of Westminster researching the role of quantum optimisation in health and disease. This area of research is looking at how quantum effects can be used to help optimise life conditions for living systems.
Professor Guy is in the unique position of having successfully brought to market medicines derived from plants; an experience that is invaluable to the search for new medicines. Moreover, his in-depth knowledge of the biotech market and medical community is highly relevant to many sectors of society including Medicine, Business and the Social Sciences.
Professor Jimmy Bell from the University of Westminster’s Research Centre for Optimal Health who is the organiser of this Public Lecture, said: “Understanding and adapting to global research challenges will be key to deliver the next revolution in medicine.”
The evening lecture will take place between 6.30-8pm on Wednesday 18 October at the University of Westminster’s Cavendish Campus at 115 New Cavendish Street, London, W1W 6UW.
About the University of Westminster:
The University of Westminster boasts a vibrant learning environment attracting more than 20,000 students from over 150 nations and we continue to invest in our future with new developments, research projects and new ideas.
We offer highly attractive practice-based courses that are independently rated as excellent, many with international recognition. Our distinguished 175-year history has meant we lead the way in many areas of research, particularly politics, media, art and design, architecture and biomedical sciences, and our position in the city of London allows us to continue to build on our close connections with leading figures and organisations in these areas as well as in the worlds of business, information technology, politics and law.
Our commitment to educating graduates for the needs of professional life attracts high quality students from within the UK and around the globe.
Internationalisation, employability and sustainability are key elements in the University of Westminster’s vision for the future and we strive to ensure the very highest standards are met and maintained.